- $106.26m
- $425.51m
- $103.46m
- 18
- 96
- 12
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 1.96 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.99 | ||
| EV to EBITDA | 8.4 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | 37.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 88.17 | 295.67 | 98.02 | 156.31 | 103.46 | 106.7 | 179.52 | -7.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Directors
- Garo Armen CHM (68)
- Evan Kearns CCO (40)
- Christine Klaskin VFN (54)
- Steven Oday OTH (60)
- Timothy Wright LED (63)
- Brian Corvese IND (63)
- Susan Hirsch IND (68)
- Allison Jeynes-Ellis IND (55)
- Wadih Jordan IND (86)
- Ulf Wiinberg IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- November 10th, 1999
- Public Since
- February 4th, 2000
- No. of Shareholders
- 360
- No. of Employees
- 316
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 36,141,682
- Address
- 3 Forbes Rd, LEXINGTON, 02421-7305
- Web
- https://agenusbio.com/
- Phone
- +1 7816744410
- Auditors
- KPMG LLP
Upcoming Events for AGEN
Q1 2026 Agenus Inc Earnings Release
Agenus Inc Annual Shareholders Meeting
Similar to AGEN
ABPRO Holdings
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Agenus share price?
As of Today at 09:07 UTC, shares in Agenus are trading at $2.94. This share price information is delayed by 15 minutes.
How has the Agenus share price performed this year?
Shares in Agenus last closed at $2.94 and the price had moved by -21.39% over the past 365 days. In terms of relative price strength the Agenus share price has underperformed the S&P500 Index by -31.67% over the past year.
What are the analyst and broker recommendations for Agenus?
The overall consensus recommendation for Agenus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Agenus dividend yield?
Agenus does not currently pay a dividend.
Does Agenus pay a dividend?
Agenus does not currently pay a dividend.
When does Agenus next pay dividends?
Agenus does not currently pay a dividend.
How do I buy Agenus shares?
To buy shares in Agenus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Agenus?
As of the previous close price of $2.94, shares in Agenus had a market capitalisation of $106.26m.
Where are Agenus shares listed?
Here are the trading details for Agenus:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AGEN
What kind of share is Agenus?
Based on an overall assessment of its quality, value and momentum Agenus is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Agenus share price forecast for 2026?
The analyst consensus target price for shares in Agenus is $12.33. That is 319.39% above the last closing price of $2.94.
Analysts covering Agenus currently have a consensus Earnings Per Share (EPS) forecast of -$0.90 for the next financial year.
Find out moreWhat is the trend in the Agenus share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agenus. Over the past six months, its share price has underperformed the S&P500 Index by -43.69%.
As of the last closing price of $2.94, shares in Agenus were trading -30.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Agenus PE Ratio?
The Agenus PE ratio based on its reported earnings over the past 12 months is 1.96. The shares last closed at $2.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Agenus?
Agenus' management team is headed by:
- Garo Armen - CHM
- Evan Kearns - CCO
- Christine Klaskin - VFN
- Steven Oday - OTH
- Timothy Wright - LED
- Brian Corvese - IND
- Susan Hirsch - IND
- Allison Jeynes-Ellis - IND
- Wadih Jordan - IND
- Ulf Wiinberg - IND